GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

251 papers

Active filtersClassification:Core

Showing 241-251 of total 251 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2017OpenAlexDirectly related591 citations

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Michael A. Nauck; Juris J. Meier; Matthew A. Cavender; Mirna Abd El Aziz; Daniel J. Drucker

Aug 28, 2017Circulation

2017OpenAlexDirectly related397 citations

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes

Deborah Hinnen

Aug 1, 2017Diabetes Spectrum

2017OpenAlexDirectly related34 citations

Mast Cell and M1 Macrophage Infiltration and Local Pro-Inflammatory Factors Were Attenuated with Incretin-Based Therapies in Obesity-Related Glomerulopathy

Jiao He; Geheng Yuan; Fangxiao Cheng; Junqing Zhang; Xiaohui Guo

Jul 24, 2017Metabolic Syndrome and Related Disorders

2015OpenAlexDirectly related192 citations

GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women

Eva W. Iepsen; J. Lundgren; Bolette Hartmann; Oluf Pedersen; Torben Hansen; Niklas Rye Jørgensen; Jens‐Erik Beck Jensen; Jens J. Holst; Sten Madsbad; Signe S. Torekov

Jun 4, 2015The Journal of Clinical Endocrinology & Metabolism

2015CrossrefDirectly related103 citations

<scp>GLP</scp> ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond

Donna Ryan; Andres Acosta

Jun 1, 2015Obesity

2014OpenAlexDirectly related594 citations

The Ethics of Childhood Obesity Treatment - from the Childhood Obesity Task Force (COTF) of European Association for the Study of Obesity (EASO)

Jens‐Christian Holm; Paulina Nowicka; Nathalie J. Farpour‐Lambert; Grace O’Malley; Maria Hassapidou; Ram Weiss; Jennifer L. Baker

Jan 1, 2014Obesity Facts

2013CrossrefDirectly related7 citations

Liraglutide pancreatitis: The ABCD nationwide liraglutide audit

REJ Ryder; KY Thong; AD Blann; SM Phillips; ND Barwell; CJG Kelly; C Semple; ML Cull; P Sen Gupta

Nov 1, 2013The British Journal of Diabetes & Vascular Disease

2011OpenAlexDirectly related352 citations

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists

Alan J. Garber

Apr 22, 2011Diabetes Care

2011CrossrefDirectly related28 citations

Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies

B. Charbonnel; B. Cariou

Feb 1, 2011Diabetes, Obesity and Metabolism

2010OpenAlexDirectly related663 citations

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

Lotte Bjerre Knudsen; Lars Wichmann Madsen; Søren Andersen; Kasper Almholt; Anne Sietske de Boer; Daniel J. Drucker; C. F. Gotfredsen; Frederikke Lihme Egerod; Anne Charlotte Hegelund; Helene Jacobsen; Søren Dyring Jacobsen; Alan C. Moses; Anne‐Marie Mølck; Henriette Svarre Nielsen; Jette Nowak; Helene Solberg; Tu D. L. Thi; Milan Zdravkovic

Mar 4, 2010Endocrinology

2010OpenAlexDirectly related552 citations

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

Masayuki Arakawa; Tomoya Mita; Kosuke Azuma; Chie Ebato; Hiromasa Goto; Takashi Nomiyama; Yoshio Fujitani; Takahisa Hirose; Ryuzo Kawamori; Hirotaka Watada

Jan 12, 2010Diabetes